Rivastigmine effects on EEG spectra and three-dimensional LORETA functional imaging in Alzheimer's disease

Gianotti, Lorena; Künig, Gabriella; Faber, Pascal L; Lehmann, Dietrich; Pascual-Marqui, Roberto D; Kochi, Kieko; Schreiter-Gasser, Ursula (2008). Rivastigmine effects on EEG spectra and three-dimensional LORETA functional imaging in Alzheimer's disease. Psychopharmacology, 198(3), pp. 323-332. Springer 10.1007/s00213-008-1111-1

[img] Text
art%3A10.1007%2Fs00213-008-1111-1.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (323kB) | Request a copy

OBJECTIVE The objective of the study is to investigate the electrocortical and the global cognitive effects of 3 months rivastigmine medication in a group of mild to moderate Alzheimer's disease patients. MATERIALS AND METHODS Multichannel EEG and cognitive performances measured with the Mini Mental State Examination in a group of 16 patients with mild to moderate Alzheimer's Disease were collected before and 3 months after the onset of rivastigmine medication. RESULTS Spectral analysis of the EEG data showed a significant power decrease in the delta and theta frequency bands during rivastigmine medication, i.e., a shift of the power spectrum towards 'normalization'. Three-dimensional low resolution electromagnetic tomography (LORETA) functional imaging localized rivastigmine effects in a network that includes left fronto-parietal regions, posterior cingulate cortex, bilateral parahippocampal regions, and the hippocampus. Moreover, a correlation analysis between differences in the cognitive performances during the two recordings and LORETA-computed intracortical activity showed, in the alpha1 frequency band, better cognitive performance with increased cortical activity in the left insula. CONCLUSION The results point to a 'normalization' of the EEG power spectrum due to medication, and the intracortical localization of these effects showed an increase of cortical activity in frontal, parietal, and temporal regions that are well-known to be affected in Alzheimer's disease. The topographic convergence of the present results with the memory network proposed by Vincent et al. (J. Neurophysiol. 96:3517-3531, 2006) leads to the speculation that in our group of patients, rivastigmine specifically activates brain regions that are involved in memory functions, notably a key symptom in this degenerative disease.

Item Type:

Journal Article (Original Article)

Division/Institute:

07 Faculty of Human Sciences > Institute of Psychology > Social Psychology and Social Neuroscience

UniBE Contributor:

Gianotti, Lorena

Subjects:

100 Philosophy > 150 Psychology

ISSN:

0033-3158

Publisher:

Springer

Language:

English

Submitter:

Lorena Gianotti

Date Deposited:

24 Dec 2014 10:29

Last Modified:

24 Dec 2014 10:29

Publisher DOI:

10.1007/s00213-008-1111-1

PubMed ID:

18446328

Uncontrolled Keywords:

Alzheimer’s disease, Rivastigmine, Cholinesterase inhibitors, EEG, Spectral analysis, Source localization, LORETA functional imaging

BORIS DOI:

10.7892/boris.61181

URI:

https://boris.unibe.ch/id/eprint/61181

Actions (login required)

Edit item Edit item
Provide Feedback